查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1842186

肝炎藥物市場規模、佔有率和趨勢分析報告：疾病、分銷管道、地區和細分市場預測，2025-2033年

Hepatitis Therapeutics Market Size, Share & Trends Analysis Report By Disease (Hepatitis A, Hepatitis B, Hepatitis C), By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies), By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

肝炎治療市場摘要

全球肝炎治療市場預計在 2024 年達到 168 億美元，預計到 2033 年將達到 236.2 億美元，2025 年至 2033 年的複合年成長率為 3.9%。

由於乙型和丙型肝炎感染的流行持續構成重大的健康挑戰，全球市場正在不斷擴大。

篩檢的改進和臨床意識的提高加速了早期診斷，從而有助於及時啟動治療。對抗病毒藥物、直接抗病毒藥物和免疫調節劑的需求仍然強勁，並構成了目前治療的基石。例如，乙型肝炎基金會報告稱，美國食品藥物管理局（FDA）核准七種藥物用於治療慢性乙型肝炎，其中包括五種口服抗病毒藥物：維瑞德（Viread）、維美利達（Vemlidy）、博來格列淨（Baraclude）、艾匹維-HBV（Epivir-HBV）和博來格列淨（Baraclude）、艾匹維-HBV（Epivir-HBV）和赫普塞拉（Hepsera），以及兩種注射免疫劑用免疫調節劑。基金會強調，治療方案的製定應考慮肝病活動度和肝硬化情況，並建議由專科醫師定期監測。治癒性丙型肝炎藥物的日益普及進一步增強了該領域的成長前景。

此外，未經治療的肝炎感染導致肝臟相關併發症（如肝硬化和肝細胞癌）的增加，推動了對先進治療方法的需求。與老化相關的併發症發生率不斷上升，使得人們更加依賴療效和安全性已得到證實的抗病毒療法。製藥公司正積極投資臨床研究，以期透過治癒率更高、耐受性更好的治療方法來滿足這些需求。例如，2025年8月，《應用臨床試驗在線》（Applied Clinical Trials Online）報告，Aligos Therapeutics公司已啟動了ALG-000184（一種First-in-Class的口服衣殼組裝調變器）的II期B-SUPREME試驗，該試驗納入了約200名治療的成年患者，其中包括慢性HBe和陰性患者。這項隨機、雙盲試驗旨在比較ALG-000184單藥治療與富馬酸替諾福韋酯治療48週的療效，主要終點為HBV DNA抑制，次要終點包括安全性、藥物動力學和抗原降低。中期結果預計於2026年公佈，主要結果預計於2027年公佈。先前的I期數據已證實ALG-000184具有持續的抗病毒活性、良好的安全性，且未發現新的安全性訊號，進一步推動了肝炎治療領域的臨床創新。

細胞免疫療法的出現正在推動肝炎治療市場的成長，尤其是在慢性感染疾病導致晚期肝臟併發症的患者中。例如，2025年5月，OncLive通報，自體HBV特異性T細胞療法SCG101在晚期HBV相關肝細胞癌中展現出抗病毒和抗腫瘤活性。在一項I期臨床試驗中，94%的患者在28天內HBsAg水平顯著降低，並維持控制長達一年，其中23.5%的患者實現了HBsAg完全清除。 47%的患者觀察到腫瘤緩解，但尚未達到中位總存活期。安全性良好，最常見的不良事件為短暫性ALT升高和細胞激素釋放症候群。這些結果凸顯了創新免疫療法在滿足未被滿足的醫療需求和促進市場擴張方面的重要作用。

目錄

第1章調查方法和範圍

第2章執行摘要

第3章 肝炎藥物市場變數、趨勢與範圍

  • 市場體系展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 商業環境分析
    • 產業分析—波特五力分析
    • PESTLE分析
    • 管道分析
    • 專利到期分析
    • 定價分析

第4章 肝炎治療市場：依疾病區分的業務分析

  • 按疾病分類的市場佔有率，2024 年和 2033 年
  • 疾病細分儀表板
  • 市場規模、預測與趨勢分析：按疾病分類，2021-2033 年
  • 甲型肝炎
  • B型肝炎
  • C型肝炎
  • 其他

第5章 肝炎治療市場：依通路分類的業務分析

  • 按分銷管道分類的市場佔有率，2024 年和 2033 年
  • 按分銷管道分類的細分儀表板
  • 按分銷管道分類的市場規模、預測和趨勢分析，2021-2033年
  • 醫院藥房
  • 藥局和藥房
  • 其他

第6章 肝炎治療藥物市場：區域估算與趨勢分析

  • 2024 年及 2033 年區域市佔率分析
  • 區域市場概覽
  • 市場規模、預測與趨勢分析：2021-2033年
  • 北美洲
    • 按國家/地區分類，2021-2033 年
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第7章 競爭情勢

  • 參與者概覽
  • 企業市場分析
  • 公司分類
  • 策略規劃
  • 公司簡介/上市公司
    • Teva Pharmaceutical Industries Ltd.
    • Bristol-Myers Squibb Company
    • F. Hoffmann-La Roche Ltd
    • Zydus Group
    • GSK plc.
    • AbbVie Inc.
    • Gilead Sciences, Inc.
    • Merck &Co., Inc.
    • Lupin
    • Cipla
Product Code: GVR-1-68038-449-9

Hepatitis Therapeutics Market Summary

The global hepatitis therapeutics market size was estimated at USD 16.80 billion in 2024 and is projected to reach USD 23.62 billion by 2033, growing at a CAGR of 3.9% from 2025 to 2033. The global market is expanding as the prevalence of hepatitis B and C infections continues to pose a significant health challenge.

Improved screening and rising clinical awareness have accelerated early diagnosis, supporting timely treatment initiation. Demand for antivirals, direct-acting antivirals, and immunomodulators remains strong, forming the backbone of current therapies. For instance, the Hepatitis B Foundation reported FDA approval of seven medications for chronic hepatitis B, including five oral antivirals: Viread, Vemlidy, Baraclude, Epivir-HBV, and Hepsera, along with two injectable immune modulators: Pegasys and Intron A. The foundation emphasized that treatment decisions should consider liver disease activity and cirrhosis, with regular specialist monitoring recommended. Rising adoption of curative hepatitis C therapies further strengthens growth prospects.

Another key driver is the rise in liver-related complications associated with untreated hepatitis infections, such as cirrhosis and hepatocellular carcinoma, which is pushing demand for advanced therapeutic approaches. The increasing burden of comorbid conditions in aging populations has heightened reliance on antiviral regimens with proven efficacy and safety. Pharmaceutical companies are actively investing in clinical research to address these needs through therapies with higher cure rates and improved tolerability. For instance, in August 2025, Applied Clinical Trials Online reported that Aligos Therapeutics had initiated dosing in its Phase II B-SUPREME trial of ALG-000184, a first-in-class oral capsid assembly modulator, in approximately 200 treatment-naive adults with chronic hepatitis B, including both HBeAg-positive and HBeAg-negative patients. The randomized, double-masked study was designed to compare ALG-000184 monotherapy with tenofovir disoproxil fumarate over 48 weeks, with primary endpoints focusing on HBV DNA suppression and secondary outcomes assessing safety, pharmacokinetics, and antigen reductions. Interim findings were expected in 2026, and topline results in 2027, while earlier Phase I data had already demonstrated sustained antiviral activity, favorable safety, and no new safety signals, reinforcing the momentum of clinical innovation in hepatitis therapeutics.

The emergence of cell-based immunotherapies is driving growth in the hepatitis therapeutics market, particularly for patients with advanced liver complications from chronic infections. For instance, in May 2025, OncLive reported that SCG101, an autologous HBV-specific T-cell therapy, delivered antiviral and antitumor activity in advanced HBV-related hepatocellular carcinoma. In a Phase I trial, 94% of patients achieved notable HBsAg reductions within 28 days, with sustained control for up to one year, while 23.5% achieved complete HBsAg loss. Tumor responses were observed in 47% of patients, and median overall survival had not been reached. Safety remained manageable, with transient ALT elevations and cytokine release syndrome being the most common events. These outcomes underscore the role of innovative immunotherapies in addressing unmet needs and strengthening market expansion.

Global Hepatitis Therapeutics Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global hepatitis therapeutics market report based on disease, distribution channel, and region:

  • Disease Outlook (Revenue, USD Million, 2021 - 2033)
  • Hepatitis A
  • Hepatitis B
  • Hepatitis C
  • Others
  • Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospital Pharmacies
  • Drug Stores and Retail Pharmacies
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Disease
    • 1.2.2. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Hepatitis Therapeutics Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Patent Expiry Analysis
    • 3.3.5. Pricing Analysis

Chapter 4. Hepatitis Therapeutics Market: Disease Business Analysis

  • 4.1. Disease Market Share, 2024 & 2033
  • 4.2. Disease Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Disease, 2021 to 2033 (USD Million)
  • 4.4. Hepatitis A
    • 4.4.1. Hepatitis A Market, 2021 - 2033 (USD Million)
  • 4.5. Hepatitis B
    • 4.5.1. Hepatitis B Market, 2021 - 2033 (USD Million)
  • 4.6. Hepatitis C
    • 4.6.1. Hepatitis C Market, 2021 - 2033 (USD Million)
  • 4.7. Others
    • 4.7.1. Others Market, 2021 - 2033 (USD Million)

Chapter 5. Hepatitis Therapeutics Market: Distribution Channel Business Analysis

  • 5.1. Distribution Channel Market Share, 2024 & 2033
  • 5.2. Distribution Channel Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by distribution channel, 2021 to 2033 (USD Million)
  • 5.4. Hospital Pharmacies
    • 5.4.1. Hospital Pharmacies Market, 2021 - 2033 (USD Million)
  • 5.5. Drug Stores and Retail Pharmacies
    • 5.5.1. Drug Stores and Retail Pharmacies Market, 2021 - 2033 (USD Million)
  • 5.6. Others
    • 5.6.1. Others Market, 2021 - 2033 (USD Million)

Chapter 6. Hepatitis Therapeutics Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2024 & 2033
  • 6.2. Regional Market Dashboard
  • 6.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
  • 6.4. North America
    • 6.4.1. North America Hepatitis Therapeutics Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
    • 6.4.2. U.S.
      • 6.4.2.1. Key Country Dynamics
      • 6.4.2.2. Type Disease Prevalence
      • 6.4.2.3. Regulatory Framework
      • 6.4.2.4. Reimbursement Framework
      • 6.4.2.5. U.S. Hepatitis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.3. Canada
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Type Disease Prevalence
      • 6.4.3.3. Regulatory Framework
      • 6.4.3.4. Reimbursement Framework
      • 6.4.3.5. U.S. Hepatitis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.4. Mexico
      • 6.4.4.1. Key Country Dynamics
      • 6.4.4.2. Type Disease Prevalence
      • 6.4.4.3. Regulatory Framework
      • 6.4.4.4. Reimbursement Framework
      • 6.4.4.5. Mexico Hepatitis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Europe
    • 6.5.1. Europe Hepatitis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.2. UK
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Type Disease Prevalence
      • 6.5.2.3. Regulatory Framework
      • 6.5.2.4. Reimbursement Framework
      • 6.5.2.5. Uk Hepatitis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.3. Germany
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Type Disease Prevalence
      • 6.5.3.3. Regulatory Framework
      • 6.5.3.4. Reimbursement Framework
      • 6.5.3.5. Germany Hepatitis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.4. France
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Type Disease Prevalence
      • 6.5.4.3. Regulatory Framework
      • 6.5.4.4. Reimbursement Framework
      • 6.5.4.5. France Hepatitis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.5. Italy
      • 6.5.5.1. Key Country Dynamics
      • 6.5.5.2. Type Disease Prevalence
      • 6.5.5.3. Regulatory Framework
      • 6.5.5.4. Reimbursement Framework
      • 6.5.5.5. Italy Hepatitis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.6. Spain
      • 6.5.6.1. Key Country Dynamics
      • 6.5.6.2. Type Disease Prevalence
      • 6.5.6.3. Regulatory Framework
      • 6.5.6.4. Reimbursement Framework
      • 6.5.6.5. Spain Hepatitis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.7. Denmark
      • 6.5.7.1. Key Country Dynamics
      • 6.5.7.2. Type Disease Prevalence
      • 6.5.7.3. Regulatory Framework
      • 6.5.7.4. Reimbursement Framework
      • 6.5.7.5. Denmark Hepatitis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.8. Sweden
      • 6.5.8.1. Key Country Dynamics
      • 6.5.8.2. Type Disease Prevalence
      • 6.5.8.3. Regulatory Framework
      • 6.5.8.4. Reimbursement Framework
      • 6.5.8.5. Sweden Hepatitis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.9. Norway
      • 6.5.9.1. Key Country Dynamics
      • 6.5.9.2. Type Disease Prevalence
      • 6.5.9.3. Regulatory Framework
      • 6.5.9.4. Reimbursement Framework
      • 6.5.9.5. Norway Hepatitis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6. Asia Pacific
    • 6.6.1. Asia Pacific Hepatitis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.2. Japan
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Type Disease Prevalence
      • 6.6.2.3. Regulatory Framework
      • 6.6.2.4. Reimbursement Framework
      • 6.6.2.5. Japan Hepatitis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.3. China
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Type Disease Prevalence
      • 6.6.3.3. Regulatory Framework
      • 6.6.3.4. Reimbursement Framework
      • 6.6.3.5. China Hepatitis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.4. India
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Type Disease Prevalence
      • 6.6.4.3. Regulatory Framework
      • 6.6.4.4. Reimbursement Framework
      • 6.6.4.5. India Hepatitis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.5. Australia
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Type Disease Prevalence
      • 6.6.5.3. Regulatory Framework
      • 6.6.5.4. Reimbursement Framework
      • 6.6.5.5. Australia Hepatitis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.6. South Korea
      • 6.6.6.1. Key Country Dynamics
      • 6.6.6.2. Type Disease Prevalence
      • 6.6.6.3. Regulatory Framework
      • 6.6.6.4. Reimbursement Framework
      • 6.6.6.5. South Korea Hepatitis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.7. Thailand
      • 6.6.7.1. Key Country Dynamics
      • 6.6.7.2. Type Disease Prevalence
      • 6.6.7.3. Regulatory Framework
      • 6.6.7.4. Reimbursement Framework
      • 6.6.7.5. Thailand Hepatitis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7. Latin America
    • 6.7.1. Latin America Hepatitis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.2. Brazil
      • 6.7.2.1. Key Country Dynamics
      • 6.7.2.2. Type Disease Prevalence
      • 6.7.2.3. Regulatory Framework
      • 6.7.2.4. Reimbursement Framework
      • 6.7.2.5. Japan Hepatitis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.3. Argentina
      • 6.7.3.1. Key Country Dynamics
      • 6.7.3.2. Type Disease Prevalence
      • 6.7.3.3. Regulatory Framework
      • 6.7.3.4. Reimbursement Framework
      • 6.7.3.5. China Hepatitis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8. Middle East and Africa
    • 6.8.1. Middle East and Africa Hepatitis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.2. South Africa
      • 6.8.2.1. Key Country Dynamics
      • 6.8.2.2. Type Disease Prevalence
      • 6.8.2.3. Regulatory Framework
      • 6.8.2.4. Reimbursement Framework
      • 6.8.2.5. South Africa Hepatitis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.3. Saudi Arabia
      • 6.8.3.1. Key Country Dynamics
      • 6.8.3.2. Type Disease Prevalence
      • 6.8.3.3. Regulatory Framework
      • 6.8.3.4. Reimbursement Framework
      • 6.8.3.5. Saudi Arabia Hepatitis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.4. UAE
      • 6.8.4.1. Key Country Dynamics
      • 6.8.4.2. Type Disease Prevalence
      • 6.8.4.3. Regulatory Framework
      • 6.8.4.4. Reimbursement Framework
      • 6.8.4.5. UAE Hepatitis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.5. Kuwait
      • 6.8.5.1. Key Country Dynamics
      • 6.8.5.2. Type Disease Prevalence
      • 6.8.5.3. Regulatory Framework
      • 6.8.5.4. Reimbursement Framework
      • 6.8.5.5. Kuwait Hepatitis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Participant Overview
  • 7.2. Company Market Position Analysis
  • 7.3. Company Categorization
  • 7.4. Strategy Mapping
  • 7.5. Company Profiles/Listing
    • 7.5.1. Teva Pharmaceutical Industries Ltd.
      • 7.5.1.1. Overview
      • 7.5.1.2. Financial Performance
      • 7.5.1.3. Disease Benchmarking
      • 7.5.1.4. Strategic Initiatives
    • 7.5.2. Bristol-Myers Squibb Company
      • 7.5.2.1. Overview
      • 7.5.2.2. Financial Performance
      • 7.5.2.3. Disease Benchmarking
      • 7.5.2.4. Strategic Initiatives
    • 7.5.3. F. Hoffmann-La Roche Ltd
      • 7.5.3.1. Overview
      • 7.5.3.2. Financial Performance
      • 7.5.3.3. Disease Benchmarking
      • 7.5.3.4. Strategic Initiatives
    • 7.5.4. Zydus Group
      • 7.5.4.1. Overview
      • 7.5.4.2. Financial Performance
      • 7.5.4.3. Disease Benchmarking
      • 7.5.4.4. Strategic Initiatives
    • 7.5.5. GSK plc.
      • 7.5.5.1. Overview
      • 7.5.5.2. Financial Performance
      • 7.5.5.3. Disease Benchmarking
      • 7.5.5.4. Strategic Initiatives
    • 7.5.6. AbbVie Inc.
      • 7.5.6.1. Overview
      • 7.5.6.2. Financial Performance
      • 7.5.6.3. Disease Benchmarking
      • 7.5.6.4. Strategic Initiatives
    • 7.5.7. Gilead Sciences, Inc.
      • 7.5.7.1. Overview
      • 7.5.7.2. Financial Performance
      • 7.5.7.3. Disease Benchmarking
      • 7.5.7.4. Strategic Initiatives
    • 7.5.8. Merck & Co., Inc.
      • 7.5.8.1. Overview
      • 7.5.8.2. Financial Performance
      • 7.5.8.3. Disease Benchmarking
      • 7.5.8.4. Strategic Initiatives
    • 7.5.9. Lupin
      • 7.5.9.1. Overview
      • 7.5.9.2. Financial Performance
      • 7.5.9.3. Disease Benchmarking
      • 7.5.9.4. Strategic Initiatives
    • 7.5.10. Cipla
      • 7.5.10.1. Overview
      • 7.5.10.2. Financial Performance
      • 7.5.10.3. Disease Benchmarking
      • 7.5.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global hepatitis therapeutics market, by region, 2021 - 2033 (USD Million)
  • Table 4 Global hepatitis therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 5 Global hepatitis therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 6 North America hepatitis therapeutics market, by country, 2021 - 2033 (USD Million)
  • Table 7 North America hepatitis therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 8 North America hepatitis therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 9 U.S hepatitis therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 10 U.S hepatitis therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 11 Canada hepatitis therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 12 Canada hepatitis therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 13 Mexico hepatitis therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 14 Mexico hepatitis therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 15 Europe hepatitis therapeutics market, by country, 2021 - 2033 (USD Million)
  • Table 16 Europe hepatitis therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 17 Europe hepatitis therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 18 UK hepatitis therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 19 UK hepatitis therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 20 Germany hepatitis therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 21 Germany hepatitis therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 22 France hepatitis therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 23 France hepatitis therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 24 Italy hepatitis therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 25 Italy hepatitis therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 26 Spain hepatitis therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 27 Spain hepatitis therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 28 Norway hepatitis therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 29 Norway hepatitis therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 30 Denmark hepatitis therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 31 Denmark hepatitis therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 32 Sweden hepatitis therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 33 Sweden hepatitis therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 34 Asia Pacific hepatitis therapeutics market, by country, 2021 - 2033 (USD Million)
  • Table 35 Asia Pacific hepatitis therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 36 Asia Pacific hepatitis therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 37 Japan hepatitis therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 38 Japan hepatitis therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 39 China hepatitis therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 40 China hepatitis therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 41 India hepatitis therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 42 India hepatitis therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 43 Australia hepatitis therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 44 Australia hepatitis therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 45 South Korea hepatitis therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 46 South Korea hepatitis therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 47 Thailand hepatitis therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 48 Thailand hepatitis therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 49 Latin America hepatitis therapeutics market, by country, 2021 - 2033 (USD Million)
  • Table 50 Latin America hepatitis therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 51 Latin America hepatitis therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 52 Brazil hepatitis therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 53 Brazil hepatitis therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 54 Argentina hepatitis therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 55 Argentina hepatitis therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 56 Middle East & Africa Hepatitis therapeutics market, by country, 2021 - 2033 (USD Million)
  • Table 57 Middle East & Africa hepatitis therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 58 Middle East & Africa hepatitis therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 59 South Africa hepatitis therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 60 South Africa hepatitis therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 61 Saudi Arabia hepatitis therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 62 Saudi Arabia hepatitis therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 63 UAE hepatitis therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 64 UAE hepatitis therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 65 Kuwait hepatitis therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 66 Kuwait hepatitis therapeutics market, by distribution channel, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Hepatitis therapeutics market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Therapeutic approach and disease outlook (USD Million)
  • Fig. 10 Competitive landscape
  • Fig. 11 Hepatitis therapeutics market dynamics
  • Fig. 12 Hepatitis therapeutics market: Porter's five forces analysis
  • Fig. 13 Hepatitis therapeutics market: PESTLE analysis
  • Fig. 14 Disease market, 2021 - 2033 (USD Million)
  • Fig. 15 Hepatitis A market, 2021 - 2033 (USD Million)
  • Fig. 16 Hepatitis B market, 2021 - 2033 (USD Million)
  • Fig. 17 Hepatitis C market, 2021 - 2033 (USD Million)
  • Fig. 18 Others market, 2021 - 2033 (USD Million)
  • Fig. 19 Distribution channel market, 2021 - 2033 (USD Million)
  • Fig. 20 Hospital pharmacies market, 2021 - 2033 (USD Million)
  • Fig. 21 Drug store and retail pharmacies market, 2021 - 2033 (USD Million)
  • Fig. 22 Others market, 2021 - 2033 (USD Million)
  • Fig. 23 Hepatitis therapeutics market revenue, by region
  • Fig. 24 Regional marketplace: Key takeaways
  • Fig. 25 North America hepatitis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 26 U.S. country dynamics
  • Fig. 27 U.S. hepatitis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 28 Canada country dynamics
  • Fig. 29 Canada hepatitis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 30 Mexico country dynamics
  • Fig. 31 Mexico hepatitis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 32 Europe hepatitis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 33 UK country dynamics
  • Fig. 34 UK hepatitis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 35 Germany country dynamics
  • Fig. 36 Germany hepatitis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 37 France country dynamics
  • Fig. 38 France hepatitis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 39 Italy country dynamics
  • Fig. 40 Italy hepatitis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 41 Spain country dynamics
  • Fig. 42 Spain hepatitis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 43 Norway country dynamics
  • Fig. 44 Norway hepatitis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 45 Sweden country dynamics
  • Fig. 46 Sweden hepatitis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 47 Denmark country dynamics
  • Fig. 48 Denmark hepatitis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 49 Asia Pacific hepatitis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 50 Japan country dynamics
  • Fig. 51 Japan hepatitis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 52 China country dynamics
  • Fig. 53 China hepatitis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 54 India country dynamics
  • Fig. 55 India hepatitis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 56 Australia country dynamics
  • Fig. 57 Australia hepatitis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 58 South Korea country dynamics
  • Fig. 59 South Korea hepatitis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 60 Thailand country dynamics
  • Fig. 61 Thailand hepatitis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 62 Latin America hepatitis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 63 Brazil country dynamics
  • Fig. 64 Brazil hepatitis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 65 Argentina country dynamics
  • Fig. 66 Argentina hepatitis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 67 MEA hepatitis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 68 South Africa country dynamics
  • Fig. 69 South Africa hepatitis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 70 Saudi Arabia country dynamics
  • Fig. 71 Saudi Arabia hepatitis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 72 UAE country dynamics
  • Fig. 73 UAE hepatitis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 74 Kuwait country dynamics
  • Fig. 75 Kuwait hepatitis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 76 Company categorization
  • Fig. 77 Company market position analysis
  • Fig. 78 Strategic framework